---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-127099"
form_type: "8-K"
ticker: null
cik: "0001834645"
company_name: "Peak Bio, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:35:49.080527+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Peak Bio completes merger with Akari; exchange ratio 0.2935, 48.4% ownership

## Summary
- Each Peak Bio share converted into 0.2935 Akari ADS; Peak stockholders own ~48.4% of combined company.
- Outstanding convertible notes with $8.4M principal converted into 19.4M Peak Bio shares pre-merger.
- Concurrent private placement of 1.71M Akari ADS and warrants raises $3.2M gross proceeds.
- All prior directors resigned; Samir R. Patel appointed President and Secretary post-merger.
- Peak Bio becomes wholly-owned subsidiary of Akari; charter and bylaws amended.

## SEC filing metadata
- accession: 0000950170-24-127099
- form_type: 8-K
- cik: 0001834645
- company_name: Peak Bio, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.01, 3.02, 3.03, 5.01, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1834645/000095017024127099/0000950170-24-127099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1834645/000095017024127099/pkbo-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-127099
- JSON: https://secwatch.observer/filing/0000950170-24-127099.json
- Plain text: https://secwatch.observer/filing/0000950170-24-127099.txt

## Key facts
- Executive change
  James Neal resigned as Director at Peak Bio, Inc..
  - Action: resigned
  - Role: Director
  source text: Hoyoung Huh, MD, PhD, James Neal and Sandip Patel resigned as directors of the Company and any committees thereof.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1834645/000095017024127099/0000950170-24-127099-index.htm
- Executive change
  Samir R. Patel was appointed as President and Secretary at Peak Bio, Inc..
  - Action: appointed
  - Role: President and Secretary
  source text: Samir R. Patel, M.D. was appointed to serve as President and Secretary of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1834645/000095017024127099/0000950170-24-127099-index.htm
- Executive change
  Hoyoung Huh resigned as Director at Peak Bio, Inc..
  - Action: resigned
  - Role: Director
  source text: Hoyoung Huh, MD, PhD, James Neal and Sandip Patel resigned as directors of the Company and any committees thereof.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1834645/000095017024127099/0000950170-24-127099-index.htm
- Executive change
  Sandip Patel resigned as Director at Peak Bio, Inc..
  - Action: resigned
  - Role: Director
  source text: Hoyoung Huh, MD, PhD, James Neal and Sandip Patel resigned as directors of the Company and any committees thereof.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1834645/000095017024127099/0000950170-24-127099-index.htm
- M&A Transactions
  Peak Bio, Inc. underwent a change of control involving Akari Therapeutics, Plc (closed 2024-11-14).
  - Action: change of control
  - Counterparty: Akari Therapeutics, Plc
  - Closing: 2024-11-14
  source text: On November 14, 2024, Peak Bio Inc. (the “Company”) completed the previously announced strategic combination (the “Closing”) contemplated by the Agreement and Plan of Merger by and among the Company, Akari Therapeutics, Plc, a public company limited by shares under the laws of England and Wales (“Akari”) and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari (“Merger Sub”), as amended by that certain side letter dated August 15, 2024 (the “Merger Agreement”), pursuant to which, upon the terms and subject to the conditions thereof, Merger Sub was merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly-owned subsidiary of Akari.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1834645/000095017024127099/0000950170-24-127099-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.